Renin-Angiotensin banner
 lift button To visit another floor: Press the lift button, use the HTML version, or go to the reception
.
Select a room

search search

Advanced Search
Related resources
CV - Hypertension
CV - Post MI
Diabetes type 2
Heart failure
NPCi blog - cardiovascular
NPCi blog - diabetes

Links
NICE guidance on Hypertension - CG34
NICE guidance on Chronic Heart Failure - CG5
NICE guidance on Type 2 diabetes - CG87
NICE guidance on MI: secondary prevention - CG48
NICE guidance on Chronic Kidney Disease - CG73
SIGN guideline on Chronic Heart Failure - No. 95

Feedback
Please help us to improve this site by filling in our feedback form


National Support Materials

Renin-Angiotensin System Drugs - patient icon Patient Decision Aid

 

Telmisartan licence change
Since these NPCi materials were published, telmisartan has been licensed for cardiovascular prevention (see Summary of Product Characteristics for details). To accompany this licence change, telmisartan has become a black triangle drug intensively monitored by the MHRA and CHM. This licence extension does not change any of the messages in these materials.

ACE-inhibitors and angiotensin-2 receptor antagonists (A2RA) drugs are used in a number of indications.  A patient decision aid related to their use in heart failure is available on the heart failure floor of NPCi

Although the patient decision aids for hypertension and type 2 diabetes do not specifically discuss ACE-inhibitors and A2RAs, they may also be useful.

 

 


                                                 Terms & Conditions
 
npci npc home